Prevention from Doxorubicin Cardiotoxicity by Available Protective Agents in Iran
Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 7, Issue 1
Abstract
Doxorubicin, used in pediatric chemotherapy regimens, has cardiotoxic effects. Dexrazoxane is co-administrated with doxorubicin to prevent its cardiotoxicity. Here we have explored some alternative food or drugs to be used in absence of dexrazoxane since it’s not readily available in Iran at this time. Keywords: Pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, Iran.
Authors and Affiliations
M Shahriari, B Abdolkarimi
Keywords
Related Articles
- EP ID EP363262
- DOI -
- Views 88
- Downloads 0
A Case of Gaucher's Disease with Recurrent Fetal Loss and Antiphospholipid Antibody Syndrome
This article has no abstract.
Serum Lipid Profile Alterations in Acute Leukemia Before and After Chemotherapy
Background: Serum lipids abnormalities have been observed in various forms of cancers including acute leukemia. Investigators report decreased total cholesterol and HDL, and elevated triglyceride in leukemic patients. Li...
Platelet Satellitism in a Three and Half Year Old Girl with Hemolytic Anemia and Normal Platelet Count
Platelet adherence surrounding leucocytes in a rosette formation or platelet satellitism is a rare phenomenon. This finding has been observed almost exclusively in Ethylenediaminetetraacetic acid treated blood at room te...
Prevalence of Delta Beta Thalassemia Minor in Southern Iran
Background: Hb A2 is elevated in subjects with beta thalassemia minor but small percent of carriers have normal Hb A2 with elevated levels of HbF (2-10%). This type of thalassemia is called delta beta thalassemia, and ca...
ALK- negative Anaplastic Large Cell Lymphoma of Bone
This article has no abstract.